Oncologic outcome and potential prognostic factors in primary squamous cell carcinoma of the parotid gland

Fang, Qigen; Wu, Junhua; Liu, Fei

doi:10.1186/s12885-019-5969-6

Cited by 25 publications

(45 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These authors found that the parotid gland was most likely to be involved, that 87.5% of the diseases were low or intermediate grade, and that most of the patients were staged as T1 or T2. Similar findings were also noted in the current study; moreover, both PNI and LVI have been found to be important prognostic factors ( 28 , 29 ). We are the first to report the rates of PNI and LVI in secondary patients, which were similar to those in primary patients.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Comparison Between Primary and Secondary Pediatric Mucoepidermoid Carcinoma of the Head and Neck

Shi

2020

Front. Pediatr.

View full text Add to dashboard Cite

Objectives: Secondary mucoepidermoid carcinoma (MEC) of the head and neck is occasionally observed in childhood cancer survivors. The goal of this research was to compare the demographic and pathologic characteristics, as well as survival between primary and secondary MEC in children and adolescent patients. Methods: Pediatric patients (younger than 19 years old) with surgically treated MEC of the head and neck were retrospectively enrolled at the Affiliated Children's Hospital of Zhengzhou University and divided into two groups based on their cancer history. Demographic, pathologic, and survival characteristics between the two groups were compared. The main study interests were recurrence-free survival (RFS), overall survival (OS), and disease-specific survival (DSS). Results: The primary and secondary groups consisted of 63 and 15 patients, respectively. The two groups had similar distributions in terms of age, sex, tumor stage, neck lymph node stage, perineural invasion, lymphovascular invasion, p53, Bcl-2, proliferating cell nuclear antigen, carcinoembryonic antigen, and Ki-67 index. The 10-year RFS rates for the primary group and secondary group were 80 and 71%, respectively, and this difference was not significant (p = 0.464). The 10-year DSS rates for the primary group and secondary group were 83 and 82%, respectively, and this difference was also not significant (p = 0.649). The 10-year OS rates for the primary group and secondary group were 74 and 51%, respectively; this difference was significant (p = 0.023). Further Cox model analysis confirmed the independence of a previous cancer history (p = 0.043) in decreasing OS. Conclusions: Pediatric patients with secondary MEC exhibit similar demographic, pathologic, and molecular characteristics as primary patients but worse OS. These findings indicate that special disease management approaches might be needed for secondary patients.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Additionally, the significance of tumor stage and cervical nodal status has been widely analyzed. Both Fang et al ( 29 ) and Seng et al ( 32 ) reported that high tumor stage and neck lymph node metastasis were related to poorer survival, and our results also support this finding.…”

Section: Discussionsupporting

confidence: 89%

Comparison Between Primary and Secondary Pediatric Mucoepidermoid Carcinoma of the Head and Neck

Shi

2020

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…Nineteen studies were included (Figure 1). 11‐13,20‐35 There were no prospective studies identified. Instead, all studies were retrospective and noncomparative trials.…”

Section: Resultsmentioning

confidence: 99%

“…Twelve studies were classified medium quality (5‐8 points) and seven studies as high quality (9‐12 points). It is important to note that nine of the studies came from the same institution, the Zhengzhou University, China, with varying time periods, inclusion criteria, and the outcome measures 13,21‐24,28,31,32,35 . All but one study were single institutional noncomparative cohort studies.…”

Section: Resultsmentioning

confidence: 99%

Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: Systematic review

et al. 2020

View full text Add to dashboard Cite

Background The prognostic importance of intraparotid lymph node metastasis (P+) in patients with primary parotid gland carcinoma is unclear. Methods Nineteen retrospective and noncomparative cohort studies, published between 1992 and 2020, met the inclusion criteria and included 2202 patients for this systematic review. Results The pooled prevalence of the P in adult patients in the unselected studies was 24.10% (95% confidence interval = 17.95‐30.25). The number of P+ lymph nodes per patient was counted in only three studies and ranged from 1 to 11. The 5‐year recurrence‐free survival rate based on Kaplan‐Meier analysis varied from 83% to 88% in P− patients compared to 36% to 54% in P+ patients. The average hazard ratio for tumor recurrence in patients with P+ compared to P− was 2.67 ± 0.58. Conclusions P+ is an independent negative prognostic factor in primary parotid gland cancer and should be included into the treatment planning.

show abstract

“…Radiotherapy can be used as adjuvant therapy in patients with risk factors [2]. Squamous cell carcinomas (SCC) of the parotid gland have a worse prognosis as compared to other malignant tumours of the parotid gland, such as adenoid cystic, mucoepidermoid, and acinic cell carcinomas [8]. Tumorigenesis of squamous cell carcinoma of the parotid gland [9] is still under discussion: While some might consider primary SCC of the salivary glands as being non-existent, the vast majority of patients report on a previous cutaneous squamous cell carcinoma (CSCC) in the head and neck area [10,11], typically 1 year after onset of disease [12].…”

Section: Introductionmentioning

confidence: 99%

Survival after parotid gland metastases of cutaneous squamous cell carcinoma of the head and neck

Meyer

Wolber

Arolt

et al. 2021

Oral Maxillofac Surg

View full text Add to dashboard Cite

Purpose Malignant tumours in the parotid gland can originate either from the gland itself or as a result of metastatic spread of other tumours, such as cutaneous squamous cell carcinomas (CSCC) of the head and neck area. The aim of this study was to analyse and compare the clinical behaviour of primary as well as CSCC metastatic parotid cancers with special emphasis on therapy and oncologic outcome. Methods Clinical and histopathological data of 342 patients with parotid gland malignomas surgically treated in a tertiary referral centre between 1987 and 2015 were retrospectively assessed. Oncologic outcomes of all cases with CSCC metastasis of the parotid gland (n = 49) were compared to those of primary parotid gland carcinomas (n = 293). Results Mean age at diagnosis was 72.3 years for CSCC patients versus 56.8 years in patients with primary parotid carcinoma. A total of 83.7% of CSCC patients were male, compared to 48.8% in the group of primary carcinomas. Forty-five out of 49 CSCC patients underwent total parotidectomy and neck dissection (91.8%). A total of 93.9% out of all CSCC patients received adjuvant radiotherapy. Five-year overall survival (OS) was 32.6% in CSCC patients versus 77.2% in primary parotid carcinoma patients. Conclusion As compared to primary parotid cancers, we could show that patients suffering from CSCC metastases to the parotid gland presented with significantly higher age and worse survival.

show abstract

Oncologic outcome and potential prognostic factors in primary squamous cell carcinoma of the parotid gland

Cited by 25 publications

References 30 publications

Comparison Between Primary and Secondary Pediatric Mucoepidermoid Carcinoma of the Head and Neck

Comparison Between Primary and Secondary Pediatric Mucoepidermoid Carcinoma of the Head and Neck

Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: Systematic review

Survival after parotid gland metastases of cutaneous squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About